SUBSTITUTED PYRROLIDINES

摘要

The invention is directed to physiologically active compounds of Formula (I): wherein one of A<1>, A<2> and A<3> represents NR<2> and the others represent C(R<3>)(R<4>); R<1> represents R<5>Z<1>-Het- or R<6>N(R<7>)-C(=O)-NH-Ar<2>-; Ar<1> represents aryldiyl or heteroaryldiyl; L<1> represents a -R<12>-R<13>-linkage (where R<12> is a direct bond or an alkylene chain, an alkenylene chain or an alkynylene chain and R<13> is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, -C(=Z<3>)-NR<11>-,-NR<11>-C(=Z<3>)-, -Z<3>-,-C(=O)-, -C(=NOR<11>)-, -NR<11>-, -NR<11>-C(=Z<3>)-NR<11>-, -SO2-NR<11>-, -NR<11>-SO2-, -O-C(=O)-, -C(=O)-O-, -NR<11>-C(=O)-O- or -O-C(=O)-NR<11>-); and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ( alpha 4 beta 1).